Ulan-Ude, Ulan-Ude, Russian Federation
The article presents the pathophysiological assessment of the results of atherogenic dyslipidemia simulation in Wistar rats. Dyslipidemia was followed by 24 % increase of triglyceride and 19 % raise of total cholesterol in blood, while the atherogenic cholesterol of low density lipoproteins increased by 39 %, and the content of anti-atherogenic cholesterol of high density lipoproteins decreased by 21 %. Furthermore, the level of modified low density lipoproteins in the blood increased by 1.8 times. On the background of lipid storage disorder the rats of the experimental group showed the signs of endothelial dysfunction: circulating endothelial cell number increased by 1.9 times, proinflammatory cytokines interleukin-1beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) increased by 21, 18 and 16 % respectively, high-sensitivity C-reactive protein (hsCRP) concentration – by 2.2 times, and fibrinogen concentration – by 17 %.
atherogenic dyslipidemia, lipid metabolism, endothelial dysfunction
1. Banzaraksheev VG (2010). Dyslipoproteinemia as a major risk factor for development and prediction of ischemic heart disease [Dislipoproteinemiya kak vedushchiy faktor riska razvitiya i prognozirovaniya ishemicheskoy bolezni serdtsa]. Kazanskaya nauka, (3), 233-235.
2. Bubnova MG, Oganov RG (2004). Impaired edible fats tolerance and its contribution to atherothrombogenesis [Narushennaya tolerantnost’ k pishchevym zhiram i ee znachenie v aterotrombogeneze]. Terapevticheskiy arkhiv, (1), 73-78.
3. Dem’yanov AV, Kotov AYu (2003). Diagnostic value of investigation of cytokine levels in clinical practice [Diagnosticheskaya tsennost’ issledovaniya urovney tsitokinov v klinicheskoy praktike]. Tsitokiny i vospalenie, (2), 20-35.
4. Zhuravleva MV (2011). Primary and secondary prevention of atherosclerosis [Pervichnaya i vtorichnaya profilaktika ateroskleroza]. Vrach, (5), 45-49.
5. Kamyshnikov VS (2000). Guide on clinico-biochemical diagnostics [Spravochnik po kliniko-biokhimicheskoy laboratornoy diagnostike], 463.
6. Men’shchikova EB, Zenkov NK, Bondar’ IA, Trufakin VA (2008). Oxidative stress: pathological conditions and diseases [Okislitel’nyy stress: Patologicheskie sostoyaniya i zabolevaniya], 284.
7. Petukhov VA (2008). Endothelial dysfunction: current state of the problem [Endotelial’naya disfunktsiya: sovremennoe sostoyanie voprosa]. Consilium Medicum, (1), 3-11.
8. Sergienko VI, Bondareva IB (2001). Mathematical statistics in clinical studies [Matematicheskaya statistika v klinicheskikh issledovaniyakh], 256.
9. Khabriev RU (2005). Manual on the experimental (preclinical) study of new pharmacological substances [Rukovodstvo po eksperimental’nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv], 832.
10. Shoybonov BB, Baronets VYu, Panchenko LF, Pal’tsyn AA (2012). A simple method for determination of modified low-density lipoproteins [Prostoy sposob opredeleniya modifitsirovannykh lipoproteinov nizkoy plotnosti]. Patologicheskaya fiziologiya i eksperimental’naya terapiya, (2), 77-82.
11. Hladovec J (1978). The method of study of endothelial dysfunction. Physiol. Bohemosbv., 27, 140-144.
12. Packard RR, Libby Р (2008). Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem., 54, 24-38.
13. Virella G, Lopes-Virella MF (2008). Atherosclerosis and humoral immune response to modified lipoproteins. Ahterosclerosis, 20, 239-246.
